These are the generic equivalent of Ingrezza capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc, it added. Valbenazine capsules had estimated annual sales of USD 1,235 million in the US, the company said, citing IQVIA MAT December 2022 data.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/baXYWNL
via IFTTT
0 comments:
Post a Comment